As the pressures increase to source safe, reliable pharmaceuticals that represent good value for money, the arrival of Actavis in the hospital sector is welcome news.
Actavis offers customers fast access to an extremely wide choice of top quality drugs and has the capacity to produce over 130 million ampoules and over 30 million vials a year.
World-class products
Actavis’ hospital portfolio includes a comprehensive oncology range comprising over 30 molecules. These products are currently sold in markets all over the globe including the EU, US and Japan. In addition to it’s own label pharmaceuticals, Actavis produces a range of oncology and non oncology injectable products for a range of commercial clients. These include branded companies such Pfizer and many of the leading generic houses, thus allowing other companies to take advantage of our manufacturing pedigree and scale. You may already be using Actavis produced products without even knowing it.
First-class facilities
In 2006, Actavis acquired Sindan Pharma, a leading European company specialising in the manufacture and distribution of oncology products. The company’s Romanian facility manufactures approximately two million vials a year of both freeze-dried and solution oncology products for sale across Europe, the US and Japan. GMP-approved by the European (EMEA), US (FDA) and Japanese regulatory authorities, the site is now the major supplier of generic Epirubicin into the Japanese market.
In January 2008, Actavis further strengthened its injectables and R&D platform when it acquired an approved premier injectable-manufacturing plant in Nerviano, Italy from Pfizer. The site is one of the largest facilities of its kind in Europe, with the capability to produce more than 30 million vials per year of both cytotoxic and non-cytotoxic injectable products - a figure which equates to around 20% of all the vials sold in France in a given year (Source: IMS).
Protection for people working with cytotoxics
Actavis has redesigned its entire range of drug packaging, incorporating best practice in the pharmaceutical sector. From 2009, most markets will be able to order oncology products with either Onco-Guard or VialShield technologies, which are designed to minimise breakage and occupational exposure. Actavis also offers extended physico-chemical stability data for major cytotoxics, designed in response to customer feedback.
A growing portfolio
To date, Actavis has marketed over 50 hospital products, with a focus on oncology medicines and a growing range of anti-infectives, local anaesthetics and analgesics. That number is set to rise rapidly, with around 550 applications pending worldwide for injectable medicines. Actavis’ highly ambitious hospitals pipeline is made up of more than 60 new projects developed both internally and through established relationships with other developers.
Looking ahead, the Company continues to work closely with a number of partners to bring a range of ready-to-use and complex products to market over the next three years.